Skip to content

Sumitovant Biopharma Logo

  • Home
  • Technology
  • Pipeline
  • Our Companies
  • Leadership
    • Leadership Voices
  • News & Events
  • Join Us
  • Contact
  • All
  • Altavant
  • Enzyvant
  • Myovant
  • Spirovant
  • Sumitovant
  • Urovant
  • February 18, 2021Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID
  • February 17, 2021Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
  • February 12, 2021Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
  • February 11, 2021Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
  • February 11, 2021Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter Fiscal Year 2020
  • January 26, 2021Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership
  • January 26, 2021Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
  • January 26, 2021Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
  • January 06, 2021Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
  • January 04, 2021Sumitovant Biopharma Announces the Appointment of Industry Veteran, David Marek, as Chief Executive Officer of Myovant Sciences
  • 1 2 3 … 16 Next »
  • Careers
  • Privacy Policy
  • Terms of Use

Sumitovant Biopharma, Inc.

151 W. 42nd Street, 15th Floor

New York, NY 10036

info@sumitovant.com

© 2021 Sumitovant Biopharma

Sumitovant is a trademark of Sumitomo Dainippon Pharma Co., Ltd.